Loading...
Repurposing FDA approved drugs against the human fungal pathogen, Candida albicans
BACKGROUND: The high cost and prolonged timeline of new drug discovery and development are major roadblocks to creating therapies for infectious diseases. Candida albicans is an opportunistic fungal pathogen that is the most common cause of fatal fungal infections in humans and costs $2–4 billion do...
Na minha lista:
| Udgivet i: | Ann Clin Microbiol Antimicrob |
|---|---|
| Main Authors: | , , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
BioMed Central
2015
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4462072/ https://ncbi.nlm.nih.gov/pubmed/26054754 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12941-015-0090-4 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|